The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Mosunetuzumab in B-NHL R/R to CAR-T
Stephen Schuster, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, discusses the ongoing phase I/Ib study (GO29781; NCT02500407) of mosunetuzumab in patients with B-cell non-Hodgkin lymphoma (NHL), who are relapsed/refractory (R/R) to CAR-T therapies or for whom a delay in effective therapy excludes this approach. Preliminary data support that mosunetuzumab has favorable tolerability and durable efficacy in heavily pre-treated R/R B-cell NHL. Prof. Schuster reveals that sequencing this antibody with CAR-T, or combining them, allows for the targetting of more than one antigen and can even benefit the development of additional agents. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
